Junshi Biosciences (HKG:1877, SHA:688180) dosed the first patient in a phase III trial of JS203, its bispecific antibody candidate for relapsed or refractory diffuse large B-cell lymphoma.
The trial will compare JS203 combined with chemotherapy against rituximab plus chemotherapy in 282 patients, according to a Friday Hong Kong bourse filing. Overall survival is the primary endpoint.
Shares of the biopharmaceutical company fell 1% by midday Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.